Global Bacterial Vaginosis Drugs

Bacterial Vaginosis Drugs Comprehensive Study by Type (Oral, Topical), Application (Pelvic Inflammatory Disease, Preterm Delivery of Infants, Urinary Tract Infection, Sexually Transmitted Diseases (STD)), Sales Channel (Direct Channel, Indirect Channel), Topical Route (Metronidazole, Clindamycin, Retention Gels (Viva Gel,Canesbalance)), End user (Hospitals, Drugs Stores, Others), Oral Route (Metronidazole, Tinidazole, Clindamycin), Mode of Drugs (Rx, OTC (Over the Counter)) Players and Region - Global Market Outlook to 2030

Bacterial Vaginosis Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Bacterial Vaginosis (BV) is the most common type of vaginal infection affecting women aged between 15-44 years of age. It is Characterized by an Imbalance between the Naturally occurring Vaginal Lactobacilli and Disease causing Bacteria which is a major cause of Vaginal Infection. BV is also highly Prevalent in Pregnant Women. It is expected that around 15% of the Pregnant Women in the United States suffer from BV. Moreover, Oral antibiotics are the first-choice treatment in pregnant women with BV. Vaginal odor (the most common, and often initial, symptom of BV) often recognized only after sexual intercourse. Common drug classes include lincosamide antibiotics and nitroimidazole antibiotics.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer AG (Germany), Pfizer Inc. (United States), Sanofi S.A. (France), The Piramal Group (India), Abbott Laboratories (United States), Galderma S.A. (Switzerland), Alkem Laboratories (India), Xiuzheng Pharmaceutical Co.Ltd. (China), Teva Pharmaceuticals Industries Ltd. (Israel), Perrigo PLC (Ireland) and Hikma (United States)


According to AMA, the market for Bacterial Vaginosis Drugs is expected to register a CAGR of 8.7% during the forecast period to 2028. This growth is primarily driven by Emerging Countries with Bacterial Vaginosis Drugs, Unmet Demands Related to Bacterial Vaginosis Treatment Market, The Government Initiatives to Increase Awareness Regarding Women’s Health and Increasing Prevalence of Infectious Diseases like Bacterial Vaginosis.

Globally, a noticeable market trend is evident Growing awareness about the controlled use of antibiotics The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Bayer AG (Germany), Pfizer Inc. (United States), Sanofi S.A. (France), The Piramal Group (India), Abbott Laboratories (United States), Galderma S.A. (Switzerland), Alkem Laboratories (India), Xiuzheng Pharmaceutical Co.Ltd. (China), Teva Pharmaceuticals Industries Ltd. (Israel), Perrigo PLC (Ireland) and Hikma (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The BV drugs market is highly fragmented due to the presence of numerous International and Regional players who are involved in producing Generic Drugs. Small companies are competing strongly with large established vendors. The growth of the vendors in the BV infection treatment market is influenced by factors such as the High prevalence of Infectious Disease and the lack of effective BV treatment. Introduction of new drugs by key companies is expected to propel the market growth.

Key Developments in the Market:
In December 2021, Daré Bioscience, Inc. received approval from FDA for its XACIATO, clindamycin phosphate vaginal gel to treat bacterial vaginosis in adult women. The approval will create significant opportunities for the company as well as accelerate the development of differentiated products for women.
In February 2022, Lupin Limited received approval from USFDA for its new drug application, SOLOSEC for bacterial vaginosis treatment. It is the first single-dose oral prescription drug that is used for 12 years of age or older female patients with bacterial vaginosis and trichomoniasis.

Regulatory Insights:
In September 2017, The Food and Drug Administration (FDA) has approved Solosec (secnidazole; Symbiomix Therapeutics) for the treatment of bacterial vaginosis in adult women, making it the first single-dose oral therapy for this indication.

Influencing Trend:
Growing awareness about the controlled use of antibiotics and Increasing Popularity about Topical Drugs & other Alternatives Treatment to the Patients

Market Growth Drivers:
Emerging Countries with Bacterial Vaginosis Drugs, Unmet Demands Related to Bacterial Vaginosis Treatment Market, The Government Initiatives to Increase Awareness Regarding Women’s Health and Increasing Prevalence of Infectious Diseases like Bacterial Vaginosis

Challenges:
Development of Resistance Against Antibiotics is posing a challenge for the market of BV drugs.

Restraints:
Side Effects related to the antibiotics treatment provided to the patients with BV may hamper the growth of the market.

Opportunities:
Unmet demand in the treatment of BV has created a great opportunity for the market players, especially the recurrent form of the disease.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Bacterial Vaginosis Drugs Market
- Analysis about New Entrants in Bacterial Vaginosis Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Bacterial Vaginosis Drugs Study Sheds Light on
— The Bacterial Vaginosis Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Bacterial Vaginosis Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Bacterial Vaginosis Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Oral
  • Topical
By Application
  • Pelvic Inflammatory Disease
  • Preterm Delivery of Infants
  • Urinary Tract Infection
  • Sexually Transmitted Diseases (STD)
By Sales Channel
  • Direct Channel
  • Indirect Channel

By Topical Route
  • Metronidazole
  • Clindamycin
  • Retention Gels (Viva Gel,Canesbalance)

By End user
  • Hospitals
  • Drugs Stores
  • Others

By Oral Route
  • Metronidazole
  • Tinidazole
  • Clindamycin

By Mode of Drugs
  • Rx
  • OTC (Over the Counter)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Emerging Countries with Bacterial Vaginosis Drugs
      • 3.2.2. Unmet Demands Related to Bacterial Vaginosis Treatment Market
      • 3.2.3. The Government Initiatives to Increase Awareness Regarding Women’s Health
      • 3.2.4. Increasing Prevalence of Infectious Diseases like Bacterial Vaginosis
    • 3.3. Market Challenges
      • 3.3.1. Development of Resistance Against Antibiotics is posing a challenge for the market of BV drugs.
    • 3.4. Market Trends
      • 3.4.1. Growing awareness about the controlled use of antibiotics
      • 3.4.2. Increasing Popularity about Topical Drugs & other Alternatives Treatment to the Patients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bacterial Vaginosis Drugs, by Type, Application, Sales Channel, Topical Route, End user, Oral Route, Mode of Drugs and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Bacterial Vaginosis Drugs (Value)
      • 5.2.1. Global Bacterial Vaginosis Drugs by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Topical
      • 5.2.2. Global Bacterial Vaginosis Drugs by: Application (Value)
        • 5.2.2.1. Pelvic Inflammatory Disease
        • 5.2.2.2. Preterm Delivery of Infants
        • 5.2.2.3. Urinary Tract Infection
        • 5.2.2.4. Sexually Transmitted Diseases (STD)
      • 5.2.3. Global Bacterial Vaginosis Drugs by: Sales Channel (Value)
        • 5.2.3.1. Direct Channel
        • 5.2.3.2. Indirect Channel
      • 5.2.4. Global Bacterial Vaginosis Drugs by: Topical Route (Value)
        • 5.2.4.1. Metronidazole
        • 5.2.4.2. Clindamycin
        • 5.2.4.3. Retention Gels (Viva Gel,Canesbalance)
      • 5.2.5. Global Bacterial Vaginosis Drugs by: End user (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Drugs Stores
        • 5.2.5.3. Others
      • 5.2.6. Global Bacterial Vaginosis Drugs by: Oral Route (Value)
        • 5.2.6.1. Metronidazole
        • 5.2.6.2. Tinidazole
        • 5.2.6.3. Clindamycin
      • 5.2.7. Global Bacterial Vaginosis Drugs by: Mode of Drugs (Value)
        • 5.2.7.1. Rx
        • 5.2.7.2. OTC (Over the Counter)
      • 5.2.8. Global Bacterial Vaginosis Drugs Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Bacterial Vaginosis Drugs (Volume)
      • 5.3.1. Global Bacterial Vaginosis Drugs by: Type (Volume)
        • 5.3.1.1. Oral
        • 5.3.1.2. Topical
      • 5.3.2. Global Bacterial Vaginosis Drugs by: Application (Volume)
        • 5.3.2.1. Pelvic Inflammatory Disease
        • 5.3.2.2. Preterm Delivery of Infants
        • 5.3.2.3. Urinary Tract Infection
        • 5.3.2.4. Sexually Transmitted Diseases (STD)
      • 5.3.3. Global Bacterial Vaginosis Drugs by: Sales Channel (Volume)
        • 5.3.3.1. Direct Channel
        • 5.3.3.2. Indirect Channel
      • 5.3.4. Global Bacterial Vaginosis Drugs by: Topical Route (Volume)
        • 5.3.4.1. Metronidazole
        • 5.3.4.2. Clindamycin
        • 5.3.4.3. Retention Gels (Viva Gel,Canesbalance)
      • 5.3.5. Global Bacterial Vaginosis Drugs by: End user (Volume)
        • 5.3.5.1. Hospitals
        • 5.3.5.2. Drugs Stores
        • 5.3.5.3. Others
      • 5.3.6. Global Bacterial Vaginosis Drugs by: Oral Route (Volume)
        • 5.3.6.1. Metronidazole
        • 5.3.6.2. Tinidazole
        • 5.3.6.3. Clindamycin
      • 5.3.7. Global Bacterial Vaginosis Drugs by: Mode of Drugs (Volume)
        • 5.3.7.1. Rx
        • 5.3.7.2. OTC (Over the Counter)
      • 5.3.8. Global Bacterial Vaginosis Drugs Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Taiwan
          • 5.3.8.2.6. Australia
          • 5.3.8.2.7. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Bacterial Vaginosis Drugs (Price)
      • 5.4.1. Global Bacterial Vaginosis Drugs by: Type (Price)
  • 6. Bacterial Vaginosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. The Piramal Group (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galderma S.A. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alkem Laboratories (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Xiuzheng Pharmaceutical Co.Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Perrigo PLC (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hikma (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Bacterial Vaginosis Drugs Sale, by Type, Application, Sales Channel, Topical Route, End user, Oral Route, Mode of Drugs and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Bacterial Vaginosis Drugs (Value)
      • 7.2.1. Global Bacterial Vaginosis Drugs by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Topical
      • 7.2.2. Global Bacterial Vaginosis Drugs by: Application (Value)
        • 7.2.2.1. Pelvic Inflammatory Disease
        • 7.2.2.2. Preterm Delivery of Infants
        • 7.2.2.3. Urinary Tract Infection
        • 7.2.2.4. Sexually Transmitted Diseases (STD)
      • 7.2.3. Global Bacterial Vaginosis Drugs by: Sales Channel (Value)
        • 7.2.3.1. Direct Channel
        • 7.2.3.2. Indirect Channel
      • 7.2.4. Global Bacterial Vaginosis Drugs by: Topical Route (Value)
        • 7.2.4.1. Metronidazole
        • 7.2.4.2. Clindamycin
        • 7.2.4.3. Retention Gels (Viva Gel,Canesbalance)
      • 7.2.5. Global Bacterial Vaginosis Drugs by: End user (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Drugs Stores
        • 7.2.5.3. Others
      • 7.2.6. Global Bacterial Vaginosis Drugs by: Oral Route (Value)
        • 7.2.6.1. Metronidazole
        • 7.2.6.2. Tinidazole
        • 7.2.6.3. Clindamycin
      • 7.2.7. Global Bacterial Vaginosis Drugs by: Mode of Drugs (Value)
        • 7.2.7.1. Rx
        • 7.2.7.2. OTC (Over the Counter)
      • 7.2.8. Global Bacterial Vaginosis Drugs Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Bacterial Vaginosis Drugs (Volume)
      • 7.3.1. Global Bacterial Vaginosis Drugs by: Type (Volume)
        • 7.3.1.1. Oral
        • 7.3.1.2. Topical
      • 7.3.2. Global Bacterial Vaginosis Drugs by: Application (Volume)
        • 7.3.2.1. Pelvic Inflammatory Disease
        • 7.3.2.2. Preterm Delivery of Infants
        • 7.3.2.3. Urinary Tract Infection
        • 7.3.2.4. Sexually Transmitted Diseases (STD)
      • 7.3.3. Global Bacterial Vaginosis Drugs by: Sales Channel (Volume)
        • 7.3.3.1. Direct Channel
        • 7.3.3.2. Indirect Channel
      • 7.3.4. Global Bacterial Vaginosis Drugs by: Topical Route (Volume)
        • 7.3.4.1. Metronidazole
        • 7.3.4.2. Clindamycin
        • 7.3.4.3. Retention Gels (Viva Gel,Canesbalance)
      • 7.3.5. Global Bacterial Vaginosis Drugs by: End user (Volume)
        • 7.3.5.1. Hospitals
        • 7.3.5.2. Drugs Stores
        • 7.3.5.3. Others
      • 7.3.6. Global Bacterial Vaginosis Drugs by: Oral Route (Volume)
        • 7.3.6.1. Metronidazole
        • 7.3.6.2. Tinidazole
        • 7.3.6.3. Clindamycin
      • 7.3.7. Global Bacterial Vaginosis Drugs by: Mode of Drugs (Volume)
        • 7.3.7.1. Rx
        • 7.3.7.2. OTC (Over the Counter)
      • 7.3.8. Global Bacterial Vaginosis Drugs Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Taiwan
          • 7.3.8.2.6. Australia
          • 7.3.8.2.7. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Bacterial Vaginosis Drugs (Price)
      • 7.4.1. Global Bacterial Vaginosis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bacterial Vaginosis Drugs: by Type(USD Million)
  • Table 2. Bacterial Vaginosis Drugs Oral , by Region USD Million (2017-2022)
  • Table 3. Bacterial Vaginosis Drugs Topical , by Region USD Million (2017-2022)
  • Table 4. Bacterial Vaginosis Drugs: by Application(USD Million)
  • Table 5. Bacterial Vaginosis Drugs Pelvic Inflammatory Disease , by Region USD Million (2017-2022)
  • Table 6. Bacterial Vaginosis Drugs Preterm Delivery of Infants , by Region USD Million (2017-2022)
  • Table 7. Bacterial Vaginosis Drugs Urinary Tract Infection , by Region USD Million (2017-2022)
  • Table 8. Bacterial Vaginosis Drugs Sexually Transmitted Diseases (STD) , by Region USD Million (2017-2022)
  • Table 9. Bacterial Vaginosis Drugs: by Sales Channel(USD Million)
  • Table 10. Bacterial Vaginosis Drugs Direct Channel , by Region USD Million (2017-2022)
  • Table 11. Bacterial Vaginosis Drugs Indirect Channel , by Region USD Million (2017-2022)
  • Table 12. Bacterial Vaginosis Drugs: by Topical Route(USD Million)
  • Table 13. Bacterial Vaginosis Drugs Metronidazole , by Region USD Million (2017-2022)
  • Table 14. Bacterial Vaginosis Drugs Clindamycin , by Region USD Million (2017-2022)
  • Table 15. Bacterial Vaginosis Drugs Retention Gels (Viva Gel,Canesbalance) , by Region USD Million (2017-2022)
  • Table 16. Bacterial Vaginosis Drugs: by End user(USD Million)
  • Table 17. Bacterial Vaginosis Drugs Hospitals , by Region USD Million (2017-2022)
  • Table 18. Bacterial Vaginosis Drugs Drugs Stores , by Region USD Million (2017-2022)
  • Table 19. Bacterial Vaginosis Drugs Others , by Region USD Million (2017-2022)
  • Table 20. Bacterial Vaginosis Drugs: by Oral Route(USD Million)
  • Table 21. Bacterial Vaginosis Drugs Metronidazole , by Region USD Million (2017-2022)
  • Table 22. Bacterial Vaginosis Drugs Tinidazole , by Region USD Million (2017-2022)
  • Table 23. Bacterial Vaginosis Drugs Clindamycin , by Region USD Million (2017-2022)
  • Table 24. Bacterial Vaginosis Drugs: by Mode of Drugs(USD Million)
  • Table 25. Bacterial Vaginosis Drugs Rx , by Region USD Million (2017-2022)
  • Table 26. Bacterial Vaginosis Drugs OTC (Over the Counter) , by Region USD Million (2017-2022)
  • Table 27. South America Bacterial Vaginosis Drugs, by Country USD Million (2017-2022)
  • Table 28. South America Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 29. South America Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 30. South America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 31. South America Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 32. South America Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 33. South America Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 34. South America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 35. Brazil Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 36. Brazil Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 37. Brazil Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 38. Brazil Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 39. Brazil Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 40. Brazil Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 41. Brazil Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 42. Argentina Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 43. Argentina Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 44. Argentina Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 45. Argentina Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 46. Argentina Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 47. Argentina Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 48. Argentina Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 49. Rest of South America Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 50. Rest of South America Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 51. Rest of South America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 52. Rest of South America Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 53. Rest of South America Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 54. Rest of South America Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 55. Rest of South America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 56. Asia Pacific Bacterial Vaginosis Drugs, by Country USD Million (2017-2022)
  • Table 57. Asia Pacific Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 58. Asia Pacific Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 59. Asia Pacific Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 60. Asia Pacific Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 61. Asia Pacific Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 62. Asia Pacific Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 63. Asia Pacific Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 64. China Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 65. China Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 66. China Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 67. China Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 68. China Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 69. China Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 70. China Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 71. Japan Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 72. Japan Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 73. Japan Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 74. Japan Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 75. Japan Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 76. Japan Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 77. Japan Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 78. India Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 79. India Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 80. India Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 81. India Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 82. India Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 83. India Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 84. India Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 85. South Korea Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 86. South Korea Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 87. South Korea Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 88. South Korea Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 89. South Korea Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 90. South Korea Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 91. South Korea Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 92. Taiwan Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 93. Taiwan Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 94. Taiwan Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 95. Taiwan Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 96. Taiwan Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 97. Taiwan Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 98. Taiwan Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 99. Australia Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 100. Australia Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 101. Australia Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 102. Australia Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 103. Australia Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 104. Australia Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 105. Australia Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 106. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 107. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 108. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 109. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 110. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 111. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 112. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 113. Europe Bacterial Vaginosis Drugs, by Country USD Million (2017-2022)
  • Table 114. Europe Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 115. Europe Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 116. Europe Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 117. Europe Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 118. Europe Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 119. Europe Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 120. Europe Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 121. Germany Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 122. Germany Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 123. Germany Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 124. Germany Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 125. Germany Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 126. Germany Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 127. Germany Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 128. France Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 129. France Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 130. France Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 131. France Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 132. France Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 133. France Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 134. France Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 135. Italy Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 136. Italy Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 137. Italy Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 138. Italy Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 139. Italy Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 140. Italy Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 141. Italy Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 142. United Kingdom Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 143. United Kingdom Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 144. United Kingdom Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 145. United Kingdom Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 146. United Kingdom Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 147. United Kingdom Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 148. United Kingdom Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 149. Netherlands Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 150. Netherlands Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 151. Netherlands Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 152. Netherlands Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 153. Netherlands Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 154. Netherlands Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 155. Netherlands Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 156. Rest of Europe Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 157. Rest of Europe Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 158. Rest of Europe Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 159. Rest of Europe Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 160. Rest of Europe Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 161. Rest of Europe Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 162. Rest of Europe Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 163. MEA Bacterial Vaginosis Drugs, by Country USD Million (2017-2022)
  • Table 164. MEA Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 165. MEA Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 166. MEA Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 167. MEA Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 168. MEA Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 169. MEA Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 170. MEA Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 171. Middle East Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 172. Middle East Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 173. Middle East Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 174. Middle East Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 175. Middle East Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 176. Middle East Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 177. Middle East Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 178. Africa Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 179. Africa Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 180. Africa Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 181. Africa Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 182. Africa Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 183. Africa Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 184. Africa Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 185. North America Bacterial Vaginosis Drugs, by Country USD Million (2017-2022)
  • Table 186. North America Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 187. North America Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 188. North America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 189. North America Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 190. North America Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 191. North America Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 192. North America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 193. United States Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 194. United States Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 195. United States Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 196. United States Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 197. United States Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 198. United States Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 199. United States Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 200. Canada Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 201. Canada Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 202. Canada Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 203. Canada Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 204. Canada Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 205. Canada Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 206. Canada Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 207. Mexico Bacterial Vaginosis Drugs, by Type USD Million (2017-2022)
  • Table 208. Mexico Bacterial Vaginosis Drugs, by Application USD Million (2017-2022)
  • Table 209. Mexico Bacterial Vaginosis Drugs, by Sales Channel USD Million (2017-2022)
  • Table 210. Mexico Bacterial Vaginosis Drugs, by Topical Route USD Million (2017-2022)
  • Table 211. Mexico Bacterial Vaginosis Drugs, by End user USD Million (2017-2022)
  • Table 212. Mexico Bacterial Vaginosis Drugs, by Oral Route USD Million (2017-2022)
  • Table 213. Mexico Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2017-2022)
  • Table 214. Bacterial Vaginosis Drugs Sales: by Type(K Units)
  • Table 215. Bacterial Vaginosis Drugs Sales Oral , by Region K Units (2017-2022)
  • Table 216. Bacterial Vaginosis Drugs Sales Topical , by Region K Units (2017-2022)
  • Table 217. Bacterial Vaginosis Drugs Sales: by Application(K Units)
  • Table 218. Bacterial Vaginosis Drugs Sales Pelvic Inflammatory Disease , by Region K Units (2017-2022)
  • Table 219. Bacterial Vaginosis Drugs Sales Preterm Delivery of Infants , by Region K Units (2017-2022)
  • Table 220. Bacterial Vaginosis Drugs Sales Urinary Tract Infection , by Region K Units (2017-2022)
  • Table 221. Bacterial Vaginosis Drugs Sales Sexually Transmitted Diseases (STD) , by Region K Units (2017-2022)
  • Table 222. Bacterial Vaginosis Drugs Sales: by Sales Channel(K Units)
  • Table 223. Bacterial Vaginosis Drugs Sales Direct Channel , by Region K Units (2017-2022)
  • Table 224. Bacterial Vaginosis Drugs Sales Indirect Channel , by Region K Units (2017-2022)
  • Table 225. Bacterial Vaginosis Drugs Sales: by Topical Route(K Units)
  • Table 226. Bacterial Vaginosis Drugs Sales Metronidazole , by Region K Units (2017-2022)
  • Table 227. Bacterial Vaginosis Drugs Sales Clindamycin , by Region K Units (2017-2022)
  • Table 228. Bacterial Vaginosis Drugs Sales Retention Gels (Viva Gel,Canesbalance) , by Region K Units (2017-2022)
  • Table 229. Bacterial Vaginosis Drugs Sales: by End user(K Units)
  • Table 230. Bacterial Vaginosis Drugs Sales Hospitals , by Region K Units (2017-2022)
  • Table 231. Bacterial Vaginosis Drugs Sales Drugs Stores , by Region K Units (2017-2022)
  • Table 232. Bacterial Vaginosis Drugs Sales Others , by Region K Units (2017-2022)
  • Table 233. Bacterial Vaginosis Drugs Sales: by Oral Route(K Units)
  • Table 234. Bacterial Vaginosis Drugs Sales Metronidazole , by Region K Units (2017-2022)
  • Table 235. Bacterial Vaginosis Drugs Sales Tinidazole , by Region K Units (2017-2022)
  • Table 236. Bacterial Vaginosis Drugs Sales Clindamycin , by Region K Units (2017-2022)
  • Table 237. Bacterial Vaginosis Drugs Sales: by Mode of Drugs(K Units)
  • Table 238. Bacterial Vaginosis Drugs Sales Rx , by Region K Units (2017-2022)
  • Table 239. Bacterial Vaginosis Drugs Sales OTC (Over the Counter) , by Region K Units (2017-2022)
  • Table 240. South America Bacterial Vaginosis Drugs Sales, by Country K Units (2017-2022)
  • Table 241. South America Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 242. South America Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 243. South America Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 244. South America Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 245. South America Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 246. South America Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 247. South America Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 248. Brazil Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 249. Brazil Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 250. Brazil Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 251. Brazil Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 252. Brazil Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 253. Brazil Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 254. Brazil Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 255. Argentina Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 256. Argentina Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 257. Argentina Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 258. Argentina Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 259. Argentina Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 260. Argentina Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 261. Argentina Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 262. Rest of South America Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 263. Rest of South America Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 264. Rest of South America Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 265. Rest of South America Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 266. Rest of South America Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 267. Rest of South America Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 268. Rest of South America Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 269. Asia Pacific Bacterial Vaginosis Drugs Sales, by Country K Units (2017-2022)
  • Table 270. Asia Pacific Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 271. Asia Pacific Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 272. Asia Pacific Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 273. Asia Pacific Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 274. Asia Pacific Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 275. Asia Pacific Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 276. Asia Pacific Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 277. China Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 278. China Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 279. China Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 280. China Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 281. China Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 282. China Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 283. China Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 284. Japan Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 285. Japan Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 286. Japan Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 287. Japan Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 288. Japan Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 289. Japan Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 290. Japan Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 291. India Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 292. India Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 293. India Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 294. India Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 295. India Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 296. India Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 297. India Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 298. South Korea Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 299. South Korea Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 300. South Korea Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 301. South Korea Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 302. South Korea Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 303. South Korea Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 304. South Korea Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 305. Taiwan Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 306. Taiwan Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 307. Taiwan Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 308. Taiwan Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 309. Taiwan Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 310. Taiwan Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 311. Taiwan Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 312. Australia Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 313. Australia Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 314. Australia Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 315. Australia Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 316. Australia Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 317. Australia Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 318. Australia Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 319. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 320. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 321. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 322. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 323. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 324. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 325. Rest of Asia-Pacific Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 326. Europe Bacterial Vaginosis Drugs Sales, by Country K Units (2017-2022)
  • Table 327. Europe Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 328. Europe Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 329. Europe Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 330. Europe Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 331. Europe Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 332. Europe Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 333. Europe Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 334. Germany Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 335. Germany Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 336. Germany Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 337. Germany Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 338. Germany Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 339. Germany Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 340. Germany Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 341. France Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 342. France Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 343. France Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 344. France Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 345. France Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 346. France Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 347. France Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 348. Italy Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 349. Italy Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 350. Italy Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 351. Italy Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 352. Italy Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 353. Italy Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 354. Italy Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 355. United Kingdom Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 356. United Kingdom Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 357. United Kingdom Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 358. United Kingdom Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 359. United Kingdom Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 360. United Kingdom Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 361. United Kingdom Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 362. Netherlands Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 363. Netherlands Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 364. Netherlands Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 365. Netherlands Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 366. Netherlands Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 367. Netherlands Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 368. Netherlands Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 369. Rest of Europe Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 370. Rest of Europe Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 371. Rest of Europe Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 372. Rest of Europe Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 373. Rest of Europe Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 374. Rest of Europe Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 375. Rest of Europe Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 376. MEA Bacterial Vaginosis Drugs Sales, by Country K Units (2017-2022)
  • Table 377. MEA Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 378. MEA Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 379. MEA Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 380. MEA Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 381. MEA Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 382. MEA Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 383. MEA Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 384. Middle East Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 385. Middle East Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 386. Middle East Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 387. Middle East Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 388. Middle East Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 389. Middle East Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 390. Middle East Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 391. Africa Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 392. Africa Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 393. Africa Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 394. Africa Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 395. Africa Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 396. Africa Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 397. Africa Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 398. North America Bacterial Vaginosis Drugs Sales, by Country K Units (2017-2022)
  • Table 399. North America Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 400. North America Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 401. North America Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 402. North America Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 403. North America Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 404. North America Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 405. North America Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 406. United States Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 407. United States Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 408. United States Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 409. United States Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 410. United States Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 411. United States Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 412. United States Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 413. Canada Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 414. Canada Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 415. Canada Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 416. Canada Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 417. Canada Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 418. Canada Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 419. Canada Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 420. Mexico Bacterial Vaginosis Drugs Sales, by Type K Units (2017-2022)
  • Table 421. Mexico Bacterial Vaginosis Drugs Sales, by Application K Units (2017-2022)
  • Table 422. Mexico Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2017-2022)
  • Table 423. Mexico Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2017-2022)
  • Table 424. Mexico Bacterial Vaginosis Drugs Sales, by End user K Units (2017-2022)
  • Table 425. Mexico Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2017-2022)
  • Table 426. Mexico Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2017-2022)
  • Table 427. Bacterial Vaginosis Drugs: by Type(USD/Units)
  • Table 428. Company Basic Information, Sales Area and Its Competitors
  • Table 429. Company Basic Information, Sales Area and Its Competitors
  • Table 430. Company Basic Information, Sales Area and Its Competitors
  • Table 431. Company Basic Information, Sales Area and Its Competitors
  • Table 432. Company Basic Information, Sales Area and Its Competitors
  • Table 433. Company Basic Information, Sales Area and Its Competitors
  • Table 434. Company Basic Information, Sales Area and Its Competitors
  • Table 435. Company Basic Information, Sales Area and Its Competitors
  • Table 436. Company Basic Information, Sales Area and Its Competitors
  • Table 437. Company Basic Information, Sales Area and Its Competitors
  • Table 438. Company Basic Information, Sales Area and Its Competitors
  • Table 439. Bacterial Vaginosis Drugs: by Type(USD Million)
  • Table 440. Bacterial Vaginosis Drugs Oral , by Region USD Million (2023-2028)
  • Table 441. Bacterial Vaginosis Drugs Topical , by Region USD Million (2023-2028)
  • Table 442. Bacterial Vaginosis Drugs: by Application(USD Million)
  • Table 443. Bacterial Vaginosis Drugs Pelvic Inflammatory Disease , by Region USD Million (2023-2028)
  • Table 444. Bacterial Vaginosis Drugs Preterm Delivery of Infants , by Region USD Million (2023-2028)
  • Table 445. Bacterial Vaginosis Drugs Urinary Tract Infection , by Region USD Million (2023-2028)
  • Table 446. Bacterial Vaginosis Drugs Sexually Transmitted Diseases (STD) , by Region USD Million (2023-2028)
  • Table 447. Bacterial Vaginosis Drugs: by Sales Channel(USD Million)
  • Table 448. Bacterial Vaginosis Drugs Direct Channel , by Region USD Million (2023-2028)
  • Table 449. Bacterial Vaginosis Drugs Indirect Channel , by Region USD Million (2023-2028)
  • Table 450. Bacterial Vaginosis Drugs: by Topical Route(USD Million)
  • Table 451. Bacterial Vaginosis Drugs Metronidazole , by Region USD Million (2023-2028)
  • Table 452. Bacterial Vaginosis Drugs Clindamycin , by Region USD Million (2023-2028)
  • Table 453. Bacterial Vaginosis Drugs Retention Gels (Viva Gel,Canesbalance) , by Region USD Million (2023-2028)
  • Table 454. Bacterial Vaginosis Drugs: by End user(USD Million)
  • Table 455. Bacterial Vaginosis Drugs Hospitals , by Region USD Million (2023-2028)
  • Table 456. Bacterial Vaginosis Drugs Drugs Stores , by Region USD Million (2023-2028)
  • Table 457. Bacterial Vaginosis Drugs Others , by Region USD Million (2023-2028)
  • Table 458. Bacterial Vaginosis Drugs: by Oral Route(USD Million)
  • Table 459. Bacterial Vaginosis Drugs Metronidazole , by Region USD Million (2023-2028)
  • Table 460. Bacterial Vaginosis Drugs Tinidazole , by Region USD Million (2023-2028)
  • Table 461. Bacterial Vaginosis Drugs Clindamycin , by Region USD Million (2023-2028)
  • Table 462. Bacterial Vaginosis Drugs: by Mode of Drugs(USD Million)
  • Table 463. Bacterial Vaginosis Drugs Rx , by Region USD Million (2023-2028)
  • Table 464. Bacterial Vaginosis Drugs OTC (Over the Counter) , by Region USD Million (2023-2028)
  • Table 465. South America Bacterial Vaginosis Drugs, by Country USD Million (2023-2028)
  • Table 466. South America Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 467. South America Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 468. South America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 469. South America Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 470. South America Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 471. South America Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 472. South America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 473. Brazil Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 474. Brazil Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 475. Brazil Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 476. Brazil Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 477. Brazil Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 478. Brazil Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 479. Brazil Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 480. Argentina Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 481. Argentina Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 482. Argentina Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 483. Argentina Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 484. Argentina Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 485. Argentina Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 486. Argentina Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 487. Rest of South America Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 488. Rest of South America Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 489. Rest of South America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 490. Rest of South America Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 491. Rest of South America Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 492. Rest of South America Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 493. Rest of South America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 494. Asia Pacific Bacterial Vaginosis Drugs, by Country USD Million (2023-2028)
  • Table 495. Asia Pacific Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 496. Asia Pacific Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 497. Asia Pacific Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 498. Asia Pacific Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 499. Asia Pacific Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 500. Asia Pacific Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 501. Asia Pacific Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 502. China Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 503. China Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 504. China Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 505. China Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 506. China Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 507. China Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 508. China Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 509. Japan Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 510. Japan Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 511. Japan Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 512. Japan Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 513. Japan Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 514. Japan Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 515. Japan Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 516. India Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 517. India Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 518. India Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 519. India Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 520. India Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 521. India Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 522. India Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 523. South Korea Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 524. South Korea Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 525. South Korea Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 526. South Korea Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 527. South Korea Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 528. South Korea Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 529. South Korea Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 530. Taiwan Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 531. Taiwan Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 532. Taiwan Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 533. Taiwan Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 534. Taiwan Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 535. Taiwan Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 536. Taiwan Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 537. Australia Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 538. Australia Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 539. Australia Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 540. Australia Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 541. Australia Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 542. Australia Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 543. Australia Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 544. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 545. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 546. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 547. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 548. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 549. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 550. Rest of Asia-Pacific Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 551. Europe Bacterial Vaginosis Drugs, by Country USD Million (2023-2028)
  • Table 552. Europe Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 553. Europe Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 554. Europe Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 555. Europe Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 556. Europe Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 557. Europe Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 558. Europe Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 559. Germany Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 560. Germany Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 561. Germany Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 562. Germany Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 563. Germany Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 564. Germany Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 565. Germany Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 566. France Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 567. France Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 568. France Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 569. France Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 570. France Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 571. France Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 572. France Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 573. Italy Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 574. Italy Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 575. Italy Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 576. Italy Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 577. Italy Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 578. Italy Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 579. Italy Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 580. United Kingdom Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 581. United Kingdom Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 582. United Kingdom Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 583. United Kingdom Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 584. United Kingdom Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 585. United Kingdom Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 586. United Kingdom Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 587. Netherlands Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 588. Netherlands Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 589. Netherlands Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 590. Netherlands Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 591. Netherlands Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 592. Netherlands Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 593. Netherlands Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 594. Rest of Europe Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 595. Rest of Europe Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 596. Rest of Europe Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 597. Rest of Europe Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 598. Rest of Europe Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 599. Rest of Europe Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 600. Rest of Europe Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 601. MEA Bacterial Vaginosis Drugs, by Country USD Million (2023-2028)
  • Table 602. MEA Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 603. MEA Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 604. MEA Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 605. MEA Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 606. MEA Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 607. MEA Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 608. MEA Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 609. Middle East Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 610. Middle East Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 611. Middle East Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 612. Middle East Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 613. Middle East Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 614. Middle East Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 615. Middle East Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 616. Africa Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 617. Africa Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 618. Africa Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 619. Africa Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 620. Africa Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 621. Africa Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 622. Africa Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 623. North America Bacterial Vaginosis Drugs, by Country USD Million (2023-2028)
  • Table 624. North America Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 625. North America Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 626. North America Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 627. North America Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 628. North America Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 629. North America Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 630. North America Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 631. United States Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 632. United States Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 633. United States Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 634. United States Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 635. United States Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 636. United States Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 637. United States Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 638. Canada Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 639. Canada Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 640. Canada Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 641. Canada Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 642. Canada Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 643. Canada Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 644. Canada Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 645. Mexico Bacterial Vaginosis Drugs, by Type USD Million (2023-2028)
  • Table 646. Mexico Bacterial Vaginosis Drugs, by Application USD Million (2023-2028)
  • Table 647. Mexico Bacterial Vaginosis Drugs, by Sales Channel USD Million (2023-2028)
  • Table 648. Mexico Bacterial Vaginosis Drugs, by Topical Route USD Million (2023-2028)
  • Table 649. Mexico Bacterial Vaginosis Drugs, by End user USD Million (2023-2028)
  • Table 650. Mexico Bacterial Vaginosis Drugs, by Oral Route USD Million (2023-2028)
  • Table 651. Mexico Bacterial Vaginosis Drugs, by Mode of Drugs USD Million (2023-2028)
  • Table 652. Bacterial Vaginosis Drugs Sales: by Type(K Units)
  • Table 653. Bacterial Vaginosis Drugs Sales Oral , by Region K Units (2023-2028)
  • Table 654. Bacterial Vaginosis Drugs Sales Topical , by Region K Units (2023-2028)
  • Table 655. Bacterial Vaginosis Drugs Sales: by Application(K Units)
  • Table 656. Bacterial Vaginosis Drugs Sales Pelvic Inflammatory Disease , by Region K Units (2023-2028)
  • Table 657. Bacterial Vaginosis Drugs Sales Preterm Delivery of Infants , by Region K Units (2023-2028)
  • Table 658. Bacterial Vaginosis Drugs Sales Urinary Tract Infection , by Region K Units (2023-2028)
  • Table 659. Bacterial Vaginosis Drugs Sales Sexually Transmitted Diseases (STD) , by Region K Units (2023-2028)
  • Table 660. Bacterial Vaginosis Drugs Sales: by Sales Channel(K Units)
  • Table 661. Bacterial Vaginosis Drugs Sales Direct Channel , by Region K Units (2023-2028)
  • Table 662. Bacterial Vaginosis Drugs Sales Indirect Channel , by Region K Units (2023-2028)
  • Table 663. Bacterial Vaginosis Drugs Sales: by Topical Route(K Units)
  • Table 664. Bacterial Vaginosis Drugs Sales Metronidazole , by Region K Units (2023-2028)
  • Table 665. Bacterial Vaginosis Drugs Sales Clindamycin , by Region K Units (2023-2028)
  • Table 666. Bacterial Vaginosis Drugs Sales Retention Gels (Viva Gel,Canesbalance) , by Region K Units (2023-2028)
  • Table 667. Bacterial Vaginosis Drugs Sales: by End user(K Units)
  • Table 668. Bacterial Vaginosis Drugs Sales Hospitals , by Region K Units (2023-2028)
  • Table 669. Bacterial Vaginosis Drugs Sales Drugs Stores , by Region K Units (2023-2028)
  • Table 670. Bacterial Vaginosis Drugs Sales Others , by Region K Units (2023-2028)
  • Table 671. Bacterial Vaginosis Drugs Sales: by Oral Route(K Units)
  • Table 672. Bacterial Vaginosis Drugs Sales Metronidazole , by Region K Units (2023-2028)
  • Table 673. Bacterial Vaginosis Drugs Sales Tinidazole , by Region K Units (2023-2028)
  • Table 674. Bacterial Vaginosis Drugs Sales Clindamycin , by Region K Units (2023-2028)
  • Table 675. Bacterial Vaginosis Drugs Sales: by Mode of Drugs(K Units)
  • Table 676. Bacterial Vaginosis Drugs Sales Rx , by Region K Units (2023-2028)
  • Table 677. Bacterial Vaginosis Drugs Sales OTC (Over the Counter) , by Region K Units (2023-2028)
  • Table 678. South America Bacterial Vaginosis Drugs Sales, by Country K Units (2023-2028)
  • Table 679. South America Bacterial Vaginosis Drugs Sales, by Type K Units (2023-2028)
  • Table 680. South America Bacterial Vaginosis Drugs Sales, by Application K Units (2023-2028)
  • Table 681. South America Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2023-2028)
  • Table 682. South America Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2023-2028)
  • Table 683. South America Bacterial Vaginosis Drugs Sales, by End user K Units (2023-2028)
  • Table 684. South America Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2023-2028)
  • Table 685. South America Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2023-2028)
  • Table 686. Brazil Bacterial Vaginosis Drugs Sales, by Type K Units (2023-2028)
  • Table 687. Brazil Bacterial Vaginosis Drugs Sales, by Application K Units (2023-2028)
  • Table 688. Brazil Bacterial Vaginosis Drugs Sales, by Sales Channel K Units (2023-2028)
  • Table 689. Brazil Bacterial Vaginosis Drugs Sales, by Topical Route K Units (2023-2028)
  • Table 690. Brazil Bacterial Vaginosis Drugs Sales, by End user K Units (2023-2028)
  • Table 691. Brazil Bacterial Vaginosis Drugs Sales, by Oral Route K Units (2023-2028)
  • Table 692. Brazil Bacterial Vaginosis Drugs Sales, by Mode of Drugs K Units (2023-2028)
  • Table 693. Argentina Bacterial Vaginosis Drugs Sales, by Type K Units (2023-2028)
  • Table 694. Argentina Bacterial Vaginosis Drugs Sales, by Application K Units (2023-2028)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bacterial Vaginosis Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Bacterial Vaginosis Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Bacterial Vaginosis Drugs: by Sales Channel USD Million (2017-2022)
  • Figure 7. Global Bacterial Vaginosis Drugs: by Topical Route USD Million (2017-2022)
  • Figure 8. Global Bacterial Vaginosis Drugs: by End user USD Million (2017-2022)
  • Figure 9. Global Bacterial Vaginosis Drugs: by Oral Route USD Million (2017-2022)
  • Figure 10. Global Bacterial Vaginosis Drugs: by Mode of Drugs USD Million (2017-2022)
  • Figure 11. South America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 12. Asia Pacific Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 13. Europe Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 14. MEA Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 15. North America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 16. Global Bacterial Vaginosis Drugs: by Type K Units (2017-2022)
  • Figure 17. Global Bacterial Vaginosis Drugs: by Application K Units (2017-2022)
  • Figure 18. Global Bacterial Vaginosis Drugs: by Sales Channel K Units (2017-2022)
  • Figure 19. Global Bacterial Vaginosis Drugs: by Topical Route K Units (2017-2022)
  • Figure 20. Global Bacterial Vaginosis Drugs: by End user K Units (2017-2022)
  • Figure 21. Global Bacterial Vaginosis Drugs: by Oral Route K Units (2017-2022)
  • Figure 22. Global Bacterial Vaginosis Drugs: by Mode of Drugs K Units (2017-2022)
  • Figure 23. South America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 24. Asia Pacific Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 25. Europe Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 26. MEA Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 27. North America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 28. Global Bacterial Vaginosis Drugs: by Type USD/Units (2017-2022)
  • Figure 29. Global Bacterial Vaginosis Drugs share by Players 2022 (%)
  • Figure 30. Global Bacterial Vaginosis Drugs share by Players (Top 3) 2022(%)
  • Figure 31. Global Bacterial Vaginosis Drugs share by Players (Top 5) 2022(%)
  • Figure 32. BCG Matrix for key Companies
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 38. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 39. The Piramal Group (India) Revenue, Net Income and Gross profit
  • Figure 40. The Piramal Group (India) Revenue: by Geography 2022
  • Figure 41. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 42. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 43. Galderma S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Galderma S.A. (Switzerland) Revenue: by Geography 2022
  • Figure 45. Alkem Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 46. Alkem Laboratories (India) Revenue: by Geography 2022
  • Figure 47. Xiuzheng Pharmaceutical Co.Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 48. Xiuzheng Pharmaceutical Co.Ltd. (China) Revenue: by Geography 2022
  • Figure 49. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 50. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 51. Perrigo PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 52. Perrigo PLC (Ireland) Revenue: by Geography 2022
  • Figure 53. Hikma (United States) Revenue, Net Income and Gross profit
  • Figure 54. Hikma (United States) Revenue: by Geography 2022
  • Figure 55. Global Bacterial Vaginosis Drugs: by Type USD Million (2023-2028)
  • Figure 56. Global Bacterial Vaginosis Drugs: by Application USD Million (2023-2028)
  • Figure 57. Global Bacterial Vaginosis Drugs: by Sales Channel USD Million (2023-2028)
  • Figure 58. Global Bacterial Vaginosis Drugs: by Topical Route USD Million (2023-2028)
  • Figure 59. Global Bacterial Vaginosis Drugs: by End user USD Million (2023-2028)
  • Figure 60. Global Bacterial Vaginosis Drugs: by Oral Route USD Million (2023-2028)
  • Figure 61. Global Bacterial Vaginosis Drugs: by Mode of Drugs USD Million (2023-2028)
  • Figure 62. South America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 63. Asia Pacific Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 64. Europe Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 65. MEA Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 66. North America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 67. Global Bacterial Vaginosis Drugs: by Type K Units (2023-2028)
  • Figure 68. Global Bacterial Vaginosis Drugs: by Application K Units (2023-2028)
  • Figure 69. Global Bacterial Vaginosis Drugs: by Sales Channel K Units (2023-2028)
  • Figure 70. Global Bacterial Vaginosis Drugs: by Topical Route K Units (2023-2028)
  • Figure 71. Global Bacterial Vaginosis Drugs: by End user K Units (2023-2028)
  • Figure 72. Global Bacterial Vaginosis Drugs: by Oral Route K Units (2023-2028)
  • Figure 73. Global Bacterial Vaginosis Drugs: by Mode of Drugs K Units (2023-2028)
  • Figure 74. South America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 75. Asia Pacific Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 76. Europe Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 77. MEA Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 78. North America Bacterial Vaginosis Drugs Share (%), by Country
  • Figure 79. Global Bacterial Vaginosis Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • The Piramal Group (India)
  • Abbott Laboratories (United States)
  • Galderma S.A. (Switzerland)
  • Alkem Laboratories (India)
  • Xiuzheng Pharmaceutical Co.Ltd. (China)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Perrigo PLC (Ireland)
  • Hikma (United States)
Additional players considered in the study are as follows:
Harbin Pharmaceuticals Group Holding Co.Ltd.(India) , Yunnan Baiyao (China) , Starpharma Holdings (Australia) , Lupin Inc.(India) , Sun Pharmaceuticals Industries Ltd. (India) , Cardinal Health Inc. (United States) , Astrazeneca PLC (United KIngdom) , Mylan N.V (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 242 Pages 50 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bacterial Vaginosis Drugs Quantitative research analysis
Global Bacterial Vaginosis Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Bacterial Vaginosis Drugs market are Bayer AG (Germany), Pfizer Inc. (United States), Sanofi S.A. (France), The Piramal Group (India), Abbott Laboratories (United States), Galderma S.A. (Switzerland), Alkem Laboratories (India), Xiuzheng Pharmaceutical Co.Ltd. (China), Teva Pharmaceuticals Industries Ltd. (Israel), Perrigo PLC (Ireland) and Hikma (United States), to name a few.
North America is dominating the Bacterial Vaginosis Drugs Market.
"Development of Resistance Against Antibiotics is posing a challenge for the market of BV drugs." is seen as one of the major challenges by many Industry Players of Bacterial Vaginosis Drugs Market
The Bacterial Vaginosis Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Bacterial Vaginosis Drugs market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Bacterial Vaginosis Drugs Report?

Have a Query? Click Here

Other Related Reports

Sickle Cell Disease Treatment Comprehensive Study by Type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease), Application (Hospitals, Clinics, Others), Medication (Antimetabol...
$ 3650
Exosome Diagnostics and Therapeutics Comprehensive Study by Type (Diagnostic, Therapeutic), Application (Cancer Institute, Hospital, Diagnostic Center, Others), Components (Instrument, Reagent, Softw...
$ 3750
Gonorrhea Testing Comprehensive Study by Test (Nucleic Acid Amplification (NAA), Gram Stain, Enzyme-linked immunosorbent assay (ELISA), Gonorrhea Culture, Rapid test), Sample (Blood, Lymph fluid, Uri...
$ 3450
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500